Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas

Hepato-Gastroenterology

Volumn 45, Issue 21, 1998, Pages 624-633

  Miller, Alexander R ^a   Pisters, Peter W T ^a   Lee, Jeffrey E ^a   Janjan, Nora A ^a   Abbruzzese, James L ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; PACLITAXEL; RADIOSENSITIZING AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; HUMAN; NAUSEA; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; UNITED STATES; VOMITING;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PREOPERATIVE CARE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 0031853519     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167:104-111.
2. Evans DB, Lee JE, Pisters PWT: Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer, in Nyhus LM, Baker RJ, Fishcer JF (eds): Mastery of Surgery (ed 3). Boston, Little, Brown and Co, 1997, pp 1233-1249
3. Staley CA, Cleary KA, Abbruzzese JA, et al. Need for standardized pathologic staging of pancreaticoduodenectomy specimens.: Pancreas. 1996; 12:373-380.
4. Robinson EK, Lee JE, Pisters PWT, Evans DB. Reoperative pancreaticoduodenectomy for periampullary carcinoma. Am J Surg 1996;172:432-438.
5. Spitz FR, Abbruzzese JL, Lee JE, Pisters PWT, Lowy AM, Fenoglio CJ, et al Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15:928-937.
6. Freeny PC, Traverso LW, Ryan JA: Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg 1993; 165:600-605.
7. Warshaw AL, Gu Z, Wittenberg J, et al: Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990; 125:230-233.
8. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976; 37:1519-1524.
9. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447-458.
10. Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991; 21:1137-1143.
11. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217:144-148.
12. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221:59-66.
13. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221:721-731.
14. Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 1979;189:205-208.
15. Roder JD, Stein HJ, Siewert JR. Carcinoma of the periampullary region: who benefits from portal vein resection? Am J Surg 1996; 171:170-175.
16. Allema JH, Reinders ME, van Gulik TM, Van Leeuwen DJ, de Wit LT, Verbeek PC, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg 1994; 81:1642-1646.
17. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Ann Surg 1996; 223:154-162.
18. Leach SD, Lee JE, Carnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, Pisters PWT, Evans DB. Patient survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg. In press.
19. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication to resection? Ann Surg 1996; 224:342-349.
20. Kaiser MH, Ellenberg SS. Pancreatic cancer, adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899-903.
21. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer.. Cancer 1987; 59:2006-2010.
22. Ishikuwa O, Ohhigashi, H, Teshima T, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreaticoduodenal region. J Surg Oncol 1989;40:143.
23. Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980;46:1945-1949.
24. Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre-or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983;9:911-915.
25. Evans DB, Abbruzzese JL, Rich TA: Cancer of the pancreas, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5), Philadelphia, Lippincott, 1997, pp 1054-1087.
26. Staley CA, Lee JE, Cleary KR, Abbruzzese JL, Fenoglio CJ, Rich TA, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171:118-124.
27. Evans DB, Abbruzzese J, Lee J, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas [Abstract]. Proceedings of the American Society of Clinical Oncology 1994; 13:226.
28. Foo ML, Gunderson LL, Nagorney DM, McLlrath DC, van Heerden JA, Robinow JS, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/-5 fluorouracil. Int J Radiat Oncol Biol Phys 1993; 26:483-489.
29. Hoffman JP, Weese JL, Solin LJ et al. Preoperative chemoradiation for patients with resectable pancreatic adenocarcinoma: an Eastern Cooperative Oncology Group (ECOG) phase II study [Abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:201.
30. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
31. Ellis LM, Evans DB, Martin D et al: Laparoscopic feeding jejunostomy tube in oncology patients. Surg Oncol 1:245-249, 1992.
32. Holzman MD, Reintgen K, Broome A et al: The role of laparoscopy in the management of pancreatic and periampullary malignancies. Gastroenterology 110:A1392, 1996 (Abstr).
33. Friess H, Uhl W, Silva JC et al: Preoperative laparoscopy: Do we need it in patients with pancreatic malignancies? Program of the Pancreas Club 34, 1996 (Abstr).
34. Evans DB, Abbruzzese JL, Cleary KR,et al. Rapid-fractionation preoperative chemoradiation for malignant periampullary neoplasms. J. R. Coll. Surg. Edinb. 1995;40:319-323.
35. Hertel LW, Kroin JS, Misner JW, Tustin JM. Synthesis of 2-deoxy-2',2'difluro-D-ribose and 2-deoxy-2',2'difluro-D-fibofuranosyl nucleosides. Journal of Organic Chemistry 1988;53:2406.
36. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 1990;50:4417.
37. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-β-D arabinofuranosylcytosine. Cancer Res 1988;48:4024.
38. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491.
39. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2',2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
40. Tempero, M, Capadano, M, Tarassoff, P. Dose Escalation of Gemcitabine in previously untreated patients with pancreatic adenocarcinoma [Abstract]. Proceedings of the American SoCiety Clincal Oncology 1994;13:218.
41. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer [Abstract]. Proceedings of the American Society Clincal Oncology 1995;14:199.
42. Rothenberg ML, Burris HA III, Andersen JS, et al. Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU [Abstract]. Proceedings of the American Society Clincal Oncology 1995;14:198.
43. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2', 2'-difluoro-2'-deoxycytidine. Internat J Rad Onc. Biol Physics. 1996;34:867.
44. Hittelman WN, Fujii WN, Hunter N, et. al. Identification of a window of therapeutic opportunity for the combination of gemcitabine and radiation. Proceedings of the American Association for Cancer Research 1996;37:1973.
45. Rowinsky EK, Donehower RC. Paclitaxel. New England J. Med. 1995;332:10041014.
46. Liebmann J, Cook JA, Fisher J. et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl. Cancer Institute. 1994;86:441446.
47. Milas L, Hunter NR, Mason KA.et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1995;55:3564-3568.
48. Choy H, Akerley W, Glantz M., et al Concurrent Paclitaxel and radiation therapy for solid tumors. Cancer Control. 1996;3:310-318.
49. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-2655.
50. Safran H, King TP, Choy H.et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer:A phase I study. In press: J Clin Oncol.
51. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl. Cancer Institute 1989; 82:4-6.
52. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-447.
53. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348:555-557.
54. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer (suppl.) 1996; 77:1736-1740.
55. Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Koyama H, Hoshima M, Takahashi T. Angiogenesis inhibitor TNP-40 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 1996;83:1444-1447.
56. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(Choroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994; 55:5143-5147.
57. Teicher BA, Holden SA, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 1996; 38:169-177.
58. deVries C, Escobido JA, Ueno JA, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255:989-991.
59. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung WD. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47:211-218.
60. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
61. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2:821-826.
62. Rak, J, Mitsuhashi, Y, Bayko, L. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575.
63. Almoguera, C, Shibata, D, Forrester, K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549.